Eiger - Header Menu

- Live Conference Call and Webcast at 4:30 PM ET - PALO ALTO, Calif. , July 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals , Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare

July 7, 2021

Eiger BioPharmaceuticals to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference

PALO ALTO, Calif. , July 7, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President

July 6, 2021

Eiger BioPharmaceuticals Announces First Patients Dosed with Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients

- Lambda is administered as a one-time, outpatient, subcutaneous dose PALO ALTO, Calif. , July 6, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare

Eiger - Shareholder Tools

Print Page
Contact Us
RSS Feeds
Email Alerts
IR Contacts

Contact Us

Use of this website is governed by the Terms and Conditions and Privacy Policy.

Contact Us

Use of this website is governed by the Terms and Conditions and Privacy Policy.